The study highlights a significant discrepancy in treatment strategies for HER2– early breast cancer between healthcare providers and expert oncologists. The providers, unaware of recent landmark trials, often choose more intensive treatments than recommended by experts. A decision tool was developed to guide providers in selecting appropriate treatments based on expert opinions. The tool led to changes in treatment choices for 32% of providers and confirmed the best practices for 46%. The study emphasizes the importance of support tools in helping providers make informed decisions about patient care.
Na inny język
z treści źródłowej
www.medscape.com
Kluczowe wnioski z
by Randy Doting... o www.medscape.com 06-16-2023
http://www.medscape.com/viewarticle/993320Głębsze pytania